About Lineagen
Lineagen is a Healthcare company based in Salt Lake City (United States) founded in 2002, and was acquired by Bionano Genomics in August 2020. Sequencing-based diagnostic tests and services for autism are provided. Lineagen has raised $66.93 million across 7 funding rounds from investors including Hatteras Funds, Petra Capital Partners and Health Quest Capital. The company has 40 employees. Lineagen offers products and services including FirstStep Dx PLUS, NextStep Dx PLUS, OGM-Dx Postnatal Whole Genome SV, and OGM-Dx Prenatal Whole Genome SV. Its focus areas include Life Sciences, Neurology, In-Vitro Diagnostics and Neurodevelopmental Disorders. Its legal entity is LINEAGEN INC. Its competitors include Invitae, Myriad Genetics and Genome Medical; 2 of its 3 listed competitors have raised funding.
Company details
Lineagen was founded in 2002 and is based in Salt Lake City, United States. Diagnostic tests based on sequencing technology, along with consultative services, are offered to physicians evaluating children with autism or developmental delays. Support is extended to parents through these resources. Digital platforms including m-chat.org for online screening tools and OpenAutism.com for specialist information exchange are maintained in the healthcare sector focused on neurodevelopmental disorders.
- Headquarters Salt Lake City, United States
- Employees 40
- Stage Acquired
- SectorsHealthcare
- Website lineagen.com
- Social LinkedIn X Instagram
- Acquired by Bionano Genomics (Aug 2020)
- Legal Name Lineagen Inc
- Total Equity Funding$66.93M (USD)
in 7 rounds
- Latest Funding Round$12.17M (USD), Series C
Jan 2015
- InvestorsHatteras Funds
& 11 more
- Employee Count40
- Acquired byBionano Genomics
(Aug 2020)
Products & Services of Lineagen
Lineagen offers a comprehensive portfolio of products and services, including FirstStep Dx PLUS, NextStep Dx PLUS, OGM-Dx Postnatal Whole Genome SV, and OGM-Dx Prenatal Whole Genome SV.
Diagnostic test for pediatric neurodevelopmental disorders using chromosomal microarray.
Service for whole exome sequencing to identify genetic variants.
Assessment of structural variants in postnatal genome testing.
Prenatal testing for genome structural variants.
Funding Insights of Lineagen
Lineagen has successfully raised a total of $66.93M across 7 strategic funding rounds. The most recent funding activity was a Series C round of $12.17 million completed in January 2015. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $66.93M
- Total Rounds 7
- Last Round Series C — $12.17M
- First Round $1.1M
(Jun 2010)
- Investors Count 11
All 7 funding rounds of Lineagen with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2015 | $12.17M | Series C | – | Health Quest Capital | |
| Nov 2013 | $16.11M | Series C | – | – | |
| Nov 2013 | $16.11M | Series B | – | – | |
| Apr 2013 | $11.59M | Series B | – | – | – |
| Feb 2013 | $150,000 | Series B | – | – | – |
| Aug 2010 | $10.8M | Series A | – | Prairiegold Venture Partners, Sanderling Ventures | – |
| Jun 2010 | $1.1M | Debt – Conventional | – | – | – |
12 investors in total: 12 institutional.
Investors in Lineagen
Lineagen has secured backing from 12 investors, including venture fund and institutional investors. Prominent investors backing the company include Hatteras Funds, Petra Capital Partners and Health Quest Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Multiple sectors are invested in by this private equity fund. | petracapital.com | Nashville, United States | ||
Investments are focused on tech and life sciences startups. | healthquestcapital.com | Belmont, United States | ||
Venture capital is directed toward life sciences and technology sectors. | mtngp.com | Nashville, United States | ||
Biomedical investment financing and active management services. | sanderling.com | |||
Venture capital funding is provided to innovative technology startups. | pgvp.com | Sioux Falls, United States | ||
| mesaverdevp.com | ||||
Student-managed venture capital fund | uventurefund.com | Salt Lake City, United States | ||
Diversified investments are managed across various asset classes. | 2003 | hatterasfunds.com | Raleigh, United States | |
Early-stage investments in US tech and life sciences are targeted. | spv.com | Salt Lake City, United States | ||
| archipelcapital.com |
Investor details for Lineagen
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Lineagen
4 dated milestones of Lineagen across 18 years, from founding to its latest funding, stage changes and deals.
- Founded Lineagen is founded.
- Funding First funding round of $1.1M.
- Funding Latest funding round, Series C, of $12.2M.
- Exit Acquired by Bionano Genomics.
Competitors of Lineagen
Lineagen has 3 listed competitors in our database, 2 of them funded. They include Invitae, Myriad Genetics and Genome Medical.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| invitae.com | 2010 | San Francisco, United States | $189.56M | 1,700 | Home-based genetic tests for detecting diseases are provided to individuals. | |
| myriad.com | 1991 | United States | 2,700 | Molecular diagnostics and personalized medicine for cancer are developed. | ||
| genomemedical.com | 2016 | Monterey, United States | $172.98M | 84 | Genomic testing services are provided clinically and directly to consumers. |
Detailed competitors of Lineagen
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Lineagen
Websites that share an audience with Lineagen (lineagen.com).
Websites whose visitors overlap most with Lineagen. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
autismcareuk.com | autismcareuk.com | 100% | #2,495,453 | – | |
| mapmygene.com | 98% | #8,021,007 | View details | ||
| generom.com | 98% | View details | |||
agre.org | agre.org | 63% | – | ||
conquerfragilex.org | conquerfragilex.org | 60% | – | ||
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 6 similar websites and full traffic analytics for Lineagen
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 6 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Lineagen (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Lineagen
Complete news archive for Lineagen
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Lineagen
Lineagen was founded in 2002 and raised its 1st funding round 8 years after it was founded.
Lineagen is headquartered in Salt Lake City, United States. It is registered at Salt Lake City, Utah, United States.
Lineagen is a funded company, having raised a total of $66.93M across 7 funding rounds to date. The company's 1st funding round was a Debt – Conventional of $1.1M, raised on Jun 2010.
Lineagen has 40 employees.
Lineagen was founded in 2002 and is based in Salt Lake City, United States. Diagnostic tests based on sequencing technology, along with consultative services, are offered to physicians evaluating children with autism or developmental delays. Support is extended to parents through these resources. Digital platforms including m-chat.org for online screening tools and OpenAutism.com for specialist information exchange are maintained in the healthcare sector focused on neurodevelopmental disorders.
Lineagen's top competitors include Myriad Genetics, Genome Medical and Invitae.
Lineagen offers FirstStep Dx PLUS, NextStep Dx PLUS, OGM-Dx Postnatal Whole Genome SV, and OGM-Dx Prenatal Whole Genome SV.
Lineagen has 12 investors. Key investors include Hatteras Funds, Petra Capital Partners, Health Quest Capital, Mountain Group Partners, and Sanderling Ventures.
Lineagen operates through Lineagen Inc.
Yes. Lineagen was acquired by Bionano Genomics in August 2020.